Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study.
作者信息
Molina Jesús, Plaza Vicente, Nuevo Javier, Gutiérrez Martín, Sicras-Mainar Antoni, Valero Antonio
机构信息
CS Francia, Dirección Asistencial Oeste, Fuenlabrada, 28943 Madrid, Spain.
Servei de Pneumologia i Al·lèrgia, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
出版信息
Open Respir Arch. 2023 Jan 13;5(2):100232. doi: 10.1016/j.opresp.2023.100232. eCollection 2023 Apr-Jun.
Abstract
摘要
相似文献
1
Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study.
Open Respir Arch. 2023 Jan 13;5(2):100232. doi: 10.1016/j.opresp.2023.100232. eCollection 2023 Apr-Jun.
2
Economic Consequences of the Overuse of Short-Acting ß-Adrenergic Agonists in the Treatment of Asthma in Spain.
J Investig Allergol Clin Immunol. 2023 Apr 18;33(2):109-118. doi: 10.18176/jiaci.0767. Epub 2021 Nov 26.
3
Overprescription of short-acting β-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study.
Expert Rev Respir Med. 2022 Jul;16(7):833-847. doi: 10.1080/17476348.2022.2099841. Epub 2022 Aug 24.
4
SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study.
J Asthma Allergy. 2022 Mar 24;15:371-379. doi: 10.2147/JAA.S350393. eCollection 2022.
5
Over-prescription of short-acting β-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study.
Curr Med Res Opin. 2022 Nov;38(11):1983-1995. doi: 10.1080/03007995.2022.2100649. Epub 2022 Aug 27.
6
A Cross-Sectional Study on Prescription Patterns of Short-Acting β-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort.
J Asthma Allergy. 2022 Aug 26;15:1167-1178. doi: 10.2147/JAA.S365009. eCollection 2022.
7
Over-prescription of short-acting β-agonists and asthma management in the Gulf region: a multicountry observational study.
Asthma Res Pract. 2022 Jul 7;8(1):3. doi: 10.1186/s40733-022-00085-5.
8
Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.01872-2019. Print 2020 Apr.
9
Landscape of short-acting beta-agonists (SABA) overuse in Europe.
Clin Exp Allergy. 2023 Feb;53(2):132-144. doi: 10.1111/cea.14250. Epub 2022 Dec 5.
10
Short-acting β2-agonists over-prescription in patients with asthma: an Indian subset analysis of international SABINA III study.
J Asthma. 2023 Jul;60(7):1347-1358. doi: 10.1080/02770903.2022.2147079. Epub 2022 Dec 15.
引用本文的文献
1
Too Much SAMA, Too Many Exacerbations: A Call for Caution in Asthma.
J Clin Med. 2025 Jul 16;14(14):5046. doi: 10.3390/jcm14145046.
2
Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis.
Allergy. 2025 Jun;80(6):1629-1646. doi: 10.1111/all.16538. Epub 2025 Jun 10.
3
Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations.
BMC Pulm Med. 2024 Oct 21;24(1):524. doi: 10.1186/s12890-024-03327-9.
4
The Design of a Persuasive Game to Motivate People with Asthma in Adherence to Their Maintenance Medication.
Patient Prefer Adherence. 2023 Nov 1;17:2719-2736. doi: 10.2147/PPA.S423161. eCollection 2023.
5
Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.
World Allergy Organ J. 2023 Oct 16;16(10):100823. doi: 10.1016/j.waojou.2023.100823. eCollection 2023 Oct.
本文引用的文献
1
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2297-2309.e10. doi: 10.1016/j.jaip.2022.02.047. Epub 2022 Mar 29.
2
[The management of asthma as a chronic inflammatory disease and global health problem: A position paper from the scientific societies].
Semergen. 2020 Jul-Aug;46(5):347-354. doi: 10.1016/j.semerg.2020.01.001. Epub 2020 Mar 26.
3
SABINA: An Overview of Short-Acting β-Agonist Use in Asthma in European Countries.
Adv Ther. 2020 Mar;37(3):1124-1135. doi: 10.1007/s12325-020-01233-0. Epub 2020 Jan 24.
4
Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.01872-2019. Print 2020 Apr.
5
The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity.
Eur Respir J. 2018 Nov 1;52(5). doi: 10.1183/13993003.00694-2018. Print 2018 Nov.
6
Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
N Engl J Med. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274.
7
As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
N Engl J Med. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.
8
The impact of inappropriate use of short acting beta agonists in asthma.
Respir Med. 2017 Oct;131:135-140. doi: 10.1016/j.rmed.2017.08.014. Epub 2017 Aug 17.
9
After asthma: redefining airways diseases.
Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11.
10
[Use of resources and costs associated with non-adherence to inhaled corticosteroid treatment in asthma].
Semergen. 2018 Jan-Feb;44(1):13-22. doi: 10.1016/j.semerg.2017.03.005. Epub 2017 Apr 26.
Zotero 插件